# Epithalon

> Evidence tier B — Small human studies · Longevity & Immune · reviewed 2026-11-08
> Source page: https://peptidemeta.com/p/epithalon/

Also known as: Epitalon, Epithalone, AEDG

## Quick answers

**What is Epithalon?**

A synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Khavinson, modeled on the pineal extract epithalamin.

**How strong is the evidence for Epithalon?**

Tier B (small human studies) on the peptidemeta evidence scale. Human data are limited to small biomarker studies and an older controlled study in retinitis pigmentosa, almost all from one research group; no randomized trial exists. Most evidence is cell and animal work.

**Is Epithalon FDA-approved?**

No. Epithalon is not approved by the FDA for any use.

**Is Epithalon banned in sport?**

Yes. Epithalon is prohibited in sport by the World Anti-Doping Agency under S0 (non-approved substances).

**How does Epithalon work?**

In cultured human fibroblasts, Epithalon (Ala-Glu-Asp-Gly) was reported to induce expression of the telomerase catalytic subunit (hTERT), telomerase activity and telomere elongation. It is also proposed to stimulate pineal melatonin production and restore circadian neuroendocrine function.

**What is known about the safety of Epithalon?**

Human safety data are limited to small studies from the Khavinson group; no long-term controlled safety data exist. Theoretical concern that telomerase activation could promote cancer has not been ruled out.

## Key facts

- **Evidence tier:** B (Small human studies)
- **FDA:** not approved
- **WADA:** prohibited (S0)
- **Peptide:** yes
- **Sequence:** AEDG (4 residues)
- **Formula:** C14H22N4O9
- **Molecular weight:** 390.4 g/mol
- **Routes studied:** Subcutaneous, Intramuscular

## Overview

A synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Khavinson, modeled on the pineal extract epithalamin. In cultured human cells it has been reported to activate telomerase and lengthen telomeres; human evidence is limited to small studies.

## Mechanism

In cultured human fibroblasts, Epithalon (Ala-Glu-Asp-Gly) was reported to induce expression of the telomerase catalytic subunit (hTERT), telomerase activity and telomere elongation. It is also proposed to stimulate pineal melatonin production and restore circadian neuroendocrine function. Whether these effects occur in humans has not been established.

## Effects reported in research

_Reported outcomes, not promises; see the evidence tier._

- Telomerase activation and telomere elongation (cell culture)
- Improved circadian melatonin secretion
- Antioxidant protection at the cellular level
- Enhanced immune surveillance markers

## Safety & unknowns

Human safety data are limited to small studies from the Khavinson group; no long-term controlled safety data exist. Theoretical concern that telomerase activation could promote cancer has not been ruled out. Not FDA-approved. Little independent Western clinical data.

## Studies

- Khavinson VKh, Bondarev IE, Butyugov AA, et al. (2004). *Peptide promotes overcoming of the division limit in human somatic cell*. Bulletin of Experimental Biology and Medicine. Preclinical. https://pubmed.ncbi.nlm.nih.gov/15455129/
  In cultured human fetal lung fibroblasts, Epithalon lengthened telomeres and the treated cells divided about 10 more times than controls.
- Khavinson VKh, Bondarev IE, Butyugov AA. (2003). *Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells*. Bulletin of Experimental Biology and Medicine. Preclinical. https://pubmed.ncbi.nlm.nih.gov/12937682/
  Adding Epithalon to telomerase-negative human fetal fibroblast cultures induced telomerase catalytic-subunit expression, enzyme activity, and telomere elongation.
- Khavinson V, Razumovsky M, Trofimova S, et al. (2002). *Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa*. Neuro Endocrinology Letters. Clinical trial. https://pubmed.ncbi.nlm.nih.gov/12195242/
  Reported retinal functional improvements in rats with hereditary retinal degeneration and a positive clinical effect in most treated patients with retinitis pigmentosa in a small controlled study.
- Jain A, Gallacher DM, Issa MA, et al. (2026). *Epitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence*. International Journal of Molecular Sciences. Review. https://pubmed.ncbi.nlm.nih.gov/42884164/
  Concludes that human evidence for epitalon is limited to small physiological or biomarker studies and an older controlled study, with no adequately powered randomized trial.

## Status sources

- [Epitalon and Epithalamin: narrative review of the evidence (Int J Mol Sci 2026)](https://pubmed.ncbi.nlm.nih.gov/42884164/)
- [Khavinson et al. 2002 — epitalon in retinitis pigmentosa (controlled clinical trial)](https://pubmed.ncbi.nlm.nih.gov/12195242/)
- [PubChem CID 219042 (epitalon)](https://pubchem.ncbi.nlm.nih.gov/compound/219042)
- [WADA 2026 Prohibited List — S0 non-approved substances](https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf)

---

Educational reference only — not medical advice. No dosing information is published. Tiers rate the strength of published evidence, not effectiveness or safety.